Skip to main content


Question for Department of Health and Social Care

UIN HL3160, tabled on 18 October 2021

To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 17 March (HL14040), what assessment they have made of the reduction in cost of Liothyronine (T3) in the UK, compared to the cost of the medication in other parts of Europe.

Answered on

22 October 2021

We have made no further assessment of the price of Liothyronine relative to increased competition from marketing authorisations or the cost of medicines in other parts of Europe. Further marketing authorisation applications remain at the discretion of pharmaceutical companies.